Stephens & Co. Downgrades Catalyst Pharmaceuticals to Equal-Weight

Benzinga Newsdesk www.benzinga.com Negative 91.4%

Neg 91.4% Neu 0% Pos 0%

Stephens & Co. analyst Sudan Loganathan downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) from Overweight to Equal-Weight.